Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| ARUP Laboratories, |
RCV001811163 | SCV000883986 | likely benign | not provided | 2023-01-03 | criteria provided, single submitter | clinical testing | |
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV000781459 | SCV000919496 | uncertain significance | not specified | 2017-11-29 | criteria provided, single submitter | clinical testing | Variant summary: The HBB c.5T>C (p.Val2Ala) variant, also known as Hb Raleigh, causes a missense change involving the alteration of a conserved nucleotide and 4/4 in silico tools predict a damaging outcome for this variant (SNPsandGO not captured due to low reliability index). Functional studies showed that Hb Raleigh had a lower oxygen affinity than Hb A throughout the pH range examined but did not affect protein stability (Moo-Penn_1977, Landin_1993). Also, 2,3-diphosphoglycerate and inositol hexaphosphate cofactors addition had less effect on the oxygen affinity of Hb Raleigh than on that of Hb A with chloride ions having the opposite effect. This variant was found in 1/245880 control chromosomes (gnomAD) at a frequency of 0.0000041, which does not exceed the estimated maximal expected allele frequency of a pathogenic HBB variant (0.0111803). This variant is widely regarded as clinically silent variant. It was reported in several individuals with no clinical data (Chen_1998, Thongnoppakhun_2009, Canatan_2016,) or normal hematological values in heterozygosity (Landin_2009), including one report where it was occurring in 5 members of the same family where the proband (compound heterozygous with Hb Russ) had normal hematological values (Moo Penn_1977). In addition, an individual who had this variant in compound heterozygous state with HbS showed no specific features of hemoglobinopathy or beta-thalassemia (Sofronescu_2011). Furthermore, an individual, who was a double heterozygote for this variant and alfa gene deletion (c.a-3.7), was generally healthy but had a mild anemia due to the alfa gene deletion (Jain_2011). This structural variant produces spurious HbA1c measurement depending upon methods used, impeding the use of Hb glycosylation as a means to monitor glucose control in diabetic patients with Hb-Raleigh (Chen_1998, Vandewiele_2010, Sofronescu_2011, Singha_2011, Jain_2011). Taken together, this variant is classified as a VUS-possibly benign. |
| OMIM | RCV000016563 | SCV000036831 | other | HEMOGLOBIN RALEIGH | 2017-12-12 | no assertion criteria provided | literature only | |
| Natera, |
RCV001831571 | SCV002091620 | uncertain significance | beta Thalassemia | 2018-10-24 | no assertion criteria provided | clinical testing |